|Bid||1.38 x 28000|
|Ask||1.39 x 800|
|Day's Range||1.3500 - 1.5400|
|52 Week Range||1.3500 - 6.9900|
|Beta (3Y Monthly)||2.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves as Wall Street digests headlines about US-China trade relations, this morning's BLS Employment Situation report, and a barrage of earnings, from Apple to Exxon Mobil. Here's the performance of recent earnings (as of 10:45 am EDT, Friday): ~Thurs AMC SBUX Starbucks Corp 10.60% SYMC(E) Symantec Corp 6.43% MET Metlife Inc 4.41% X U.S. Steel Corporation 2.54% WU Western Union Co (THE) -0.25% CBS CBS Corporation -1.25% EOG EOG Resources -2.25% AAPL Apple Inc -6.72% KHC The Kraft Heinz Company -7.82% GERN(HB) Geron Corp -8.11% SHAK Shake Shack Inc -11.41% GPRO GoPro Inc Cl A -21.80% OLED Universal Display Corp -27.13% WTW Weight Watchers Intl -29.87% ~Fri BMO CVX Chevron Corporation 3.48% STX(HB) Seagate Tech 2.78% IMGN Immunogen Inc 2.69% ABBV AbbVie Inc 2.48% XOM Exxon Mobil 1.41% DUK Duke Energy Corporation 0.58% BABA Alibaba Group Holding Ltd -0.84% CBOE CBOE Glbl Mkts Inc -1.23%
Geron Corporation (NASDAQ:GERN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is GERN will Read More...
Geron Corporation (GERN) today announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk myelofibrosis (MF) patients who are relapsed or refractory to a Janus Kinase (JAK) inhibitor, were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The oral presentation was made on December 3, 2018 by John Mascarenhas, M.D., Associate Professor of Medicine in the Myeloproliferative Disorders Program of the Tisch Cancer Institute, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, and an IMbark clinical investigator.
Geron Corporation (GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS), were presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California on December 2, 2018. The oral presentation was made by David Steensma, M.D., Institute Physician at the Dana-Farber Cancer Institute and Associate Professor at Harvard Medical School, and an IMerge clinical investigator. Geron believes these results support initiating the Phase 3 portion of IMerge to address an unmet medical need for patients for whom erythropoiesis stimulating agents (ESAs) are not effective and for whom currently available therapies show only modest efficacy.
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...
MENLO PARK, Calif., Nov. 07, 2018 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to.
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Geron (GERN) delivered earnings and revenue surprises of 40.00% and -25.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had a loss of 3 cents per share. The drugmaker posted revenue of $165,000 in the period. The company's shares closed at $1.85. A year ago, they were trading ...
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American.
MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced that clinical data related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be the subject of two oral presentations at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 1-4, 2018. The abstracts, summarizing clinical data from Part 1 of IMerge in myelodysplastic syndromes and the IMbark primary analysis in myelofibrosis, were published today on the ASH website at www.hematology.org.
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed ...
Geron Corporation (GERN) today announced that it will release its third quarter 2018 financial results after the market closes on Thursday, November 1, 2018. Geron will host a conference call to discuss the third quarter results and recent events at 4:30 p.m. ET the same day. Geron is a clinical stage biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.